We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights Nike, Novartis, Wells Fargo, Broadcom and Anheuser-Busch
Read MoreHide Full Article
For Immediate Release
Chicago, IL – January 18, 2023 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Nike, Inc. (NKE - Free Report) , Novartis AG (NVS - Free Report) , Wells Fargo & Co. (WFC - Free Report) , Broadcom Inc. (AVGO - Free Report) and Anheuser-Busch InBev SA/NV (BUD - Free Report) .
Here are highlights from Tuesday’s Analyst Blog:
Top Stock Reports for Nike, Novartis and Wells Fargo
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Nike, Inc., Novartis AG and Wells Fargo & Co.. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
Shares of Nike have held up a lot better in last year's tough market; down -13.4% vs. down -26% for the Zacks Consumer Discretionary sector and the S&P 500 index's -15.7% decline. A steadily growing direct-to-consumer (DTC) business and the China reopening are some of the key positives in the Nike story.
These big-picture positives notwithstanding, the Zacks analyst flagged margin pressures due to higher costs and bigger markdowns. The company provided a bleak view for fiscal 2023 and second-quarter driven by expectations of higher markdowns during the holiday season and slowed demand for NIKE's brands, including Jordan and Converse, due to reduced discretionary spending.
The Zacks analyst believes that the gross margin headwinds and the weakness in Greater China to continue hurting NIKE results in the quarters ahead.
However, NKE's robust surprise trend continued in the fiscal first quarter with earnings and sales surpassing estimates for the ninth and fourth straight quarter, respectively.
Shares of Novartis have gained +0.6% over the past year against the Zacks Large Cap Pharmaceuticals industry's gain of +14.6%. The company has a strong and diverse portfolio. Solid momentum in key brands like psoriasis drug Cosentyx, cardiovascular drug Entresto, gene therapy Zolgensma, the oncology portfolio, and the launch of Kesimpta continue to boost performance.
The launch of additional drugs like Pluvicto, Piqray, Leqvio and Mayzent, and the label expansion of key drugs should also boost performance further. The pipeline progress is also impressive and the company has some promising candidates. Management's focus on cost savings should boost the bottom line as well.
Management recently decided to spin off its generics business Sandoz into a separate company to focus on its core pharma business. However, generic competition for key drugs and pipeline setbacks also remains a concern.
Shares of Wells Fargo have underperformed the Zacks Banks - Major Regional industry over the past year (-23.8% vs. -20.8%). The company is facing dismal non-interest income, higher provisions and weakness in the mortgage business which were the major undermining factors. Also, the rise in non-interest expenses acted as a headwind.
Wells Fargo is focused on maintaining its financial position despite several legal tensions. Also, it is likely to face challenges in improving revenues due to macroeconomic and geopolitical concerns.
Nevertheless, the company is working on its strategic initiatives, which will likely help regain the confidence of its clients and shareholders. Improving loan demand, rise in interest rates and manageable expense levels are encouraging.
Other noteworthy reports we are featuring today include Broadcom Inc. and Anheuser-Busch InBev SA/NV.
Why Haven't You Looked at Zacks' Top Stocks?
Our 5 best-performing strategies have blown away the S&P's impressive +28.8% gain in 2021. Amazingly, they soared +40.3%, +48.2%, +67.6%, +94.4%, and +95.3%. Today you can access their live picks without cost or obligation.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
The Zacks Analyst Blog Highlights Nike, Novartis, Wells Fargo, Broadcom and Anheuser-Busch
For Immediate Release
Chicago, IL – January 18, 2023 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Nike, Inc. (NKE - Free Report) , Novartis AG (NVS - Free Report) , Wells Fargo & Co. (WFC - Free Report) , Broadcom Inc. (AVGO - Free Report) and Anheuser-Busch InBev SA/NV (BUD - Free Report) .
Here are highlights from Tuesday’s Analyst Blog:
Top Stock Reports for Nike, Novartis and Wells Fargo
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Nike, Inc., Novartis AG and Wells Fargo & Co.. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today's research reports here >>>
Shares of Nike have held up a lot better in last year's tough market; down -13.4% vs. down -26% for the Zacks Consumer Discretionary sector and the S&P 500 index's -15.7% decline. A steadily growing direct-to-consumer (DTC) business and the China reopening are some of the key positives in the Nike story.
These big-picture positives notwithstanding, the Zacks analyst flagged margin pressures due to higher costs and bigger markdowns. The company provided a bleak view for fiscal 2023 and second-quarter driven by expectations of higher markdowns during the holiday season and slowed demand for NIKE's brands, including Jordan and Converse, due to reduced discretionary spending.
The Zacks analyst believes that the gross margin headwinds and the weakness in Greater China to continue hurting NIKE results in the quarters ahead.
However, NKE's robust surprise trend continued in the fiscal first quarter with earnings and sales surpassing estimates for the ninth and fourth straight quarter, respectively.
(You can read the full research report on NIKE here >>>)
Shares of Novartis have gained +0.6% over the past year against the Zacks Large Cap Pharmaceuticals industry's gain of +14.6%. The company has a strong and diverse portfolio. Solid momentum in key brands like psoriasis drug Cosentyx, cardiovascular drug Entresto, gene therapy Zolgensma, the oncology portfolio, and the launch of Kesimpta continue to boost performance.
The launch of additional drugs like Pluvicto, Piqray, Leqvio and Mayzent, and the label expansion of key drugs should also boost performance further. The pipeline progress is also impressive and the company has some promising candidates. Management's focus on cost savings should boost the bottom line as well.
Management recently decided to spin off its generics business Sandoz into a separate company to focus on its core pharma business. However, generic competition for key drugs and pipeline setbacks also remains a concern.
(You can read the full research report on Novartis here >>>)
Shares of Wells Fargo have underperformed the Zacks Banks - Major Regional industry over the past year (-23.8% vs. -20.8%). The company is facing dismal non-interest income, higher provisions and weakness in the mortgage business which were the major undermining factors. Also, the rise in non-interest expenses acted as a headwind.
Wells Fargo is focused on maintaining its financial position despite several legal tensions. Also, it is likely to face challenges in improving revenues due to macroeconomic and geopolitical concerns.
Nevertheless, the company is working on its strategic initiatives, which will likely help regain the confidence of its clients and shareholders. Improving loan demand, rise in interest rates and manageable expense levels are encouraging.
(You can read the full research report on Wells Fargo here >>>)
Other noteworthy reports we are featuring today include Broadcom Inc. and Anheuser-Busch InBev SA/NV.
Why Haven't You Looked at Zacks' Top Stocks?
Our 5 best-performing strategies have blown away the S&P's impressive +28.8% gain in 2021. Amazingly, they soared +40.3%, +48.2%, +67.6%, +94.4%, and +95.3%. Today you can access their live picks without cost or obligation.
See Stocks Free >>
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.